Fortrea HoldingsFTRE -1.13%66 EV-to-FCF is 13.77 as of Jun. 29, 2026, which is 4% above its 10-year median of 13.21. GuruFocus rates FTRE with a GF Score™ of 66/100 and a GF Value™ of $18.26 (Fairly Valued). The stock has 7 warning signs investors should review. Among 336 Biotechnology companies, Fortrea Holdings ranks better than 52.08% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fortrea Holdings's Enterprise Value is $2,621 Mil.
Fortrea Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $190 Mil. Therefore, Fortrea Holdings's EV-to-FCF for today is 13.77.
The historical rank and industry rank for Fortrea Holdings's EV-to-FCF or its related term are showing as below:
FTRE'
s EV-to-FCF Range Over the Past 10 Years
Min: -204.86 Med: 13.21 Max: 55.3
Current: 13.77
During the past 6 years, the highest EV-to-FCF of Fortrea Holdings was 55.30. The lowest was -204.86. And the median was 13.21.
FTRE's EV-to-FCF is ranked better than 52.08% of 336
companies
in the Biotechnology industry
Industry Median: 14.885
vs FTRE: 13.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fortrea Holdings's PE Ratio (TTM) for today is calculated as:
Fortrea Holdings's share price for today is $17.45.
Fortrea Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fortrea Holdings EV-to-FCF Related Terms
Fortrea Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fortrea Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fortrea Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's EV-to-FCF falls into.
Fortrea Holdings's current Enterprise Value is $2,621 Mil.
Fortrea Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $190 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (FTRE) has a EV-to-FCF of 13.77 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fortrea Holdings and its competitors. This is near median its historical median of 13.21. According to the industry distribution chart, Fortrea Holdings ranks #161 out of 336 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Fortrea Holdings' EV-to-FCF too high?
Fortrea Holdings' current EV-to-FCF of 13.77 is near median its 10-year median of 13.21. The Biotechnology industry median EV-to-FCF is 14.89. Fortrea Holdings' value of 13.77 is 7.5% below this industry median. Based on the distribution chart, Fortrea Holdings ranks #161 out of 336 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fortrea Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' EV-to-FCF compare to SEPN and MLTX?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #161 out of 336 companies for EV-to-FCF. This puts Fortrea Holdings in the upper half of its industry. The industry median EV-to-FCF is 14.89. Fortrea Holdings' value of 13.77 is 7.5% below this benchmark. While the company's 10-year median is 13.21 vs. the industry median of 14.89, Fortrea Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortrea Holdings's current EV-to-FCF of 13.77 is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fortrea Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortrea Holdings's current EV-to-FCF is 13.77, which is near median its own 10-year median of 13.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Based on GuruFocus' analysis, Fortrea Holdings (FTRE) is currently considered Fairly Valued. The stock's GF Value™ is $18.26, compared to a current price of $17.45 — trading 4.4% below its estimated fair value. The current EV-to-FCF is 13.77, which is near median its 10-year median of 13.21 and 7.5% below the Biotechnology industry median of 14.89. Fortrea Holdings' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fortrea Holdings (FTRE), the current EV-to-FCF is 13.77 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (FTRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued.
The current stock price of $17.45 is trading 4.4% below its estimated GF Value™ of $18.26.
GuruFocus considers Fortrea Holdings to be Fairly Valued.
Key valuation signals for FTRE:
EV-to-FCF: 13.77 (near median its 10-year median of 13.21)
GF Value™: $18.26 vs. price of $17.45 (4.4% below fair value)
Industry Position: 7.5% below the Biotechnology median (#161 of 336)
No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
66GF Score
Get the complete analysis for FTRE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FTRE has been successfully added to your 
